Personalized alcohol risk for people with and without HIV using genetics and medication effects
Personalizing Risk from Alcohol among HIV+/-: Genetics, Medication Toxicity and PEth
This project looks at how a person's genes, medications, and alcohol exposure together affect health risks for adults aging with or without HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11172522 on NIH RePORTER |
What this research studies
If you join, researchers will ask about your alcohol use, collect your medication list, and draw blood to measure an alcohol biomarker (PEth) and genetic markers. They will calculate frailty using medical data and standardized tools and count potentially risky medication combinations (polypharmacy and A-PIMs). The team will link these measures to health outcomes like liver disease, falls, pneumonia, delirium, hospital stays, and death using medical records and follow-up. The work compares people aging with HIV to uninfected adults to identify who faces higher risks and why.
Who could benefit from this research
Good fit: Adults aging with HIV, and older adults without HIV, who drink alcohol and take multiple prescription medications are the ideal candidates for this project.
Not a fit: People who do not drink alcohol, who are not taking prescription medications, children, or those unable or unwilling to provide blood samples are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this work could help clinicians tailor medication choices and alcohol guidance to reduce liver, brain, and other harms for people aging with HIV and others who drink.
How similar studies have performed: Previous studies have linked alcohol, polypharmacy, and frailty to worse outcomes and have used PEth and VACS tools, but combining genetic risk with medication toxicity to personalize risk is relatively new.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Justice, Amy Caroline — Yale University
- Study coordinator: Justice, Amy Caroline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.